magnifying glass
logo for Ascletis Pharma

Ascletis Pharma

Drug Stores & Pharmacies · North Carolina, United States · 38 Employees

Get Full Access

Who is Ascletis Pharma

Ascletis is an innovative R&D driven biotech with two commercial products and listed on Hong Kong Stock Exchange (Ascletis, 1672.HK). Ascletis is committed to developing and commercializing antiviral, steatohepatitis, and tumor-related innovative drugs for unmet medical needs in China and Globally. Led by a management team with deep expertise and a proven track record, Ascletis has developed into a fully integrated platform covering the entire value chain from discovery and development to manufacturing and commercialization. Ascletis' pipeline is focused primarily on three therapeutic areas: 1. HCV: one commercial stage product, one near commercial stage drug and two R&D stage drug candidates. Ganovo® (Danoprevir) is the first direct-acting anti-viral agent for hepatitis C, developed by a domestic firm in China. 2. HBV: one commercial stage product and three R&D stage drug candidates. Pegasys® (Peginterferon alfa-2a) is a leading marketed pegylated interferon for hepatitis B&C partnered with Roche. 3. NASH (Non-Alcoholic SteatoHepatitis): three R&D stage drug candidates against three different targets for combination treatments.Read More

Headquarters

Headquarters:

1002 Northridge Ln, Chapel Hill, North Carolina, 27514, United States
Phone Number

Phone Number:

(919) 928-5707
Revenue

Revenue:

$6 Million
Ascletis Pharma's Social Media
SIC Code 28,283
NAICS Code 32541,325
Popular Searches:

Ascletis Pharma Inc

Ascletis Pharma Inc.

Ascletis Inc

Ascletis

Ascletis Pharmaceuticals Co. Ltd

Top Competitors of Ascletis Pharma

Employess
234
revenue
$47 Million

1

Employess
<25
revenue
<$5 Million

2

Employess
32
revenue
$6 Million

3

Employess
26
revenue
<$5 Million

4

Employess
223
revenue
$77 Million

5

Employess
26
revenue
$5 Million

6

Ascletis Pharma's Org Chart

Jinzi Wu
Jinzi Wu

Founder, Chairman & Chief Executive...

PhonePhoneEmailEmail
Melissa Palmer
Melissa Palmer

Chief Medical Officer

PhonePhoneEmailEmail

PhonePhoneEmailEmail

PhonePhoneEmailEmail
Illustration of an envelope

Ascletis Pharma Company Metrics

Company Insights
Employee Growth Rate
Funding
Funding DateRoundAmountInvestors

Jan 02, 2017

Series B

$100M

Tasly Pharmaceuticals, Inc

Dec 01, 2015

Unspecified

$20M

Goldman Sachs

Sep 01, 2015

Private Equity

$35M

Tasly Pharmaceuticals, Inc

See More

$255M

Total Funding Amount

$100M

Most Recent Funding Amount

4

Number of Funding Rounds

Revenue
QuarterRevenue

'21 - Q1

7474000

'21 - Q2

7474000

Ascletis Pharma's Tech Stack

Google Workspace (formerly G Suite)

By

Google

DigiCert

By

DigiCert

GoDaddy DNS

By

GoDaddy.com

Bootstrap

By

Twitter
See more technologies

Ascletis Pharma News & Media

Ascletis (1672.HK) Included in MSCI China Small Cap Index

HANGZHOU and SHAOXING, China, May 16, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that it will be included in the MSCI China Small Cap Index, effective after the market close on May 31, 2022. Morgan Stanley Capital International (MSCI) is a leading...

Ascletis Announces U.S. IND Approval of ASC22 (Envafolimab) for Immune Restoration/Functional Cure of HIV-1 Infected Patients

HANGZHOU, China and SHAOXING, China, May 10, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today the Investigational New Drug (IND) application approval of ASC22 (Envafolimab) by U.S. Food and Drug Administration (FDA) for the indication of immune...

Ascletis Announces 3CLpro Inhibitor ASC11 Demonstrated Potential to be Effective Treatment for COVID-19

- In antiviral cellular assays, antiviral potency (EC90) of ASC11 is 31-fold of that of Nirmatrelvir, 120-fold of that of S-217622, 16-fold of that of PBI-0451 and 7-fold of that of EDP-235. - ASC11 is an in-house discovered oral small molecule drug candidate, targeting 3CLpro, with...
Subscribe to "Ascletis Pharma" News

Frequently Asked Questions regarding Ascletis Pharma

Where are Ascletis Pharma’s headquarters?

Ascletis Pharma’s headquarters are in 1002 Northridge Ln, Chapel Hill, North Carolina, 27514, United States

What is Ascletis Pharma’s phone number?

Ascletis Pharma’s phone number is (919) 928-5707

What is Ascletis Pharma’s official website?

Ascletis Pharma’s official website is www.ascletis.com

What is Ascletis Pharma’s Revenue?

Ascletis Pharma’s revenue is $6 Million

What is Ascletis Pharma’s SIC code?

Ascletis Pharma’s SIC: 28,283

What is Ascletis Pharma’s NAICS code?

Ascletis Pharma’s NAICS: 32541,325

How many employees are working in Ascletis Pharma?

Ascletis Pharma has 38 employees

What is Ascletis Pharma’s industry?

Ascletis Pharma is in the industry of: Drug Stores & Pharmacies, Retail

Who are Ascletis Pharma’s main competitors?

Ascletis Pharma's main competitors are: NewBridge Pharmaceuticals, Galaxy Trade, Step Pharma, Abivax

What is Ascletis Pharma's tech stack?

The technologies that are used by Ascletis Pharma are: Google Workspace (formerly G Suite), DigiCert, GoDaddy DNS, Bootstrap

Who is Ascletis Pharma's CEO?

Ascletis Pharma's CEO is Jinzi Wu

See more information about Ascletis Pharma
4.4/5 on G2 Crowd